Exelixis (NASDAQ:EXEL) Price Target Raised to $42.00 - MarketBeat

16 hours ago · TD Cowen upped their price target on Exelixis from $27.00 to $34.00 and gave the company a "buy" rating in a research report on Monday, October 21st. JMP Securities raised …

$42.00
OFF

Exelixis (NASDAQ:EXEL) Price Target Raised To $42.00 - MarketBeat

2 weeks from now

16 hours ago · TD Cowen upped their price target on Exelixis from $27.00 to $34.00 and gave the company a "buy" rating in a research report on Monday, October 21st. JMP Securities raised …

marketbeat.com

$27.00
OFF

Guggenheim Boosts Exelixis (NASDAQ:EXEL) Price Target To

2 weeks from now

Jan 7, 2025 · TD Cowen boosted their target price on shares of Exelixis from $27.00 to $34.00 and gave the company a "buy" rating in a research report on Monday, October 21st. Truist …

marketbeat.com

$37.13
OFF

15 Analysts Have This To Say About Exelixis - Exelixis (NASDAQ:EXEL)

2 weeks from now

1 day ago · In the assessment of 12-month price targets, analysts unveil insights for Exelixis, presenting an average target of $37.13, a high estimate of $42.00, and a low estimate of $29.00.

benzinga.com

$42
OFF

Exelixis (EXEL) PT Raised To $42 At Guggenheim

2 weeks from now

(Updated - January 7, 2025 7:52 AM EST) Guggenheim analyst Michael W. Schmidt raised the price target on Exelixis (NASDAQ: EXEL) to $42.00 (from $33.00) while maintaining a Buy rating.

streetinsider.com

$42.00
OFF

Guggenheim Boosts Exelixis (NASDAQ:EXEL) Price Target To $42.00

2 weeks from now

Jan 9, 2025 · Exelixis (NASDAQ:EXEL – Get Free Report) had its target price lifted by Guggenheim from $33.00 to $42.00 in a research note issued to investors on …

etfdailynews.com

$37.00
OFF

Exelixis Inc (EXEL) Stock Price & News - Google Finance

2 weeks from now

MarketBeat. 48 minutes ago. Exelixis (NASDAQ:EXEL) Price Target Raised to $37.00 at Piper Sandler. Financials. Income Statement ...

google.com

$42
OFF

Exelixis Price Target Raised To $42 From $38 At Truist

2 weeks from now

1 day ago · Truist raised the firm’s price target on Exelixis to $42 from $38 and keeps a Buy rating on the shares after its positive Q4 pre-announcement.The firm views the stock favorably, and …

businessinsider.com

$42
OFF

Exelixis Price Target Raised To $42 From $33 At Guggenheim

2 weeks from now

Jan 7, 2025 · Guggenheim analyst Michael Schmidt raised the firm’s price target on Exelixis (EXEL) to $42 from $33 and keeps a Buy rating on the shares. Late-stage pipeline asset …

nasdaq.com

$38
OFF

Exelixis Price Target Raised To $38 From $34 At RBC Capital

2 weeks from now

Dec 30, 2024 · RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib stands out as Exelixis’ most clinically …

nasdaq.com

2%
OFF

Exelixis’ Price Target Raised At Truist, Shares Rise 2% - Cbonds.com

2 weeks from now

Exelixis (NASDAQ:EXEL) shares rose more than 2% intra-day today after Truist Securities analysts increased their price target on the stock to $42, up from $38, while reaffirming a Buy …

cbonds.com

$33.69
OFF

EXEL Stock Price Target | Exelixis Analyst Ratings

2 weeks from now

This price target is based on 19 analysts offering 12 month price targets for Exelixis in the last 3 months. The average price target is $33.69, with a high forecast of $42.00 and a low forecast …

pricetargets.com

$29.00
OFF

Exelixis (NASDAQ:EXEL) Stock Price Expected To Rise, JMP

2 weeks from now

16 hours ago · Finally, HC Wainwright raised their price target on Exelixis from $29.00 to $40.00 and gave the stock a "buy" rating in a research report on Friday, January 10th. One …

marketbeat.com

$29
OFF

Exelixis Price Target Raised To $29 From $23 At Stephens

2 weeks from now

Oct 30, 2024 · Stephens analyst Sudan Loganathan raised the firm’s price target on Exelixis (EXEL) to $29 from $23 and keeps an Equal Weight rating on the shares after the company …

nasdaq.com

$40.00
OFF

Exelixis (NASDAQ:EXEL) Price Target Raised To $40.00

2 weeks from now

3 days ago · Exelixis (NASDAQ:EXEL – Free Report) had its price target lifted by HC Wainwright from $29.00 to $40.00 in a report issued on Friday,Benzinga reports. The firm currently has a …

defenseworld.net

$37.00
OFF

Exelixis (NASDAQ:EXEL) Price Target Raised To $37.00 At

2 weeks from now

2 days ago · TD Cowen boosted their price target on Exelixis from $27.00 to $34.00 and gave the company a "buy" rating in a report on Monday, October 21st. Finally, Morgan Stanley boosted …

marketbeat.com

$42
OFF

Exelixis: Truist Raises Price Target Citing Increased Sales Potential

2 weeks from now

1 day ago · The brokerage raised PT to $42 from $38 while retaining a "Buy" rating. The analysts cited expanded sales potential for Cabometyx in treating neuroendocrine tumors (NET) as a …

investing.com

140%
OFF

Exelixis (EXEL) Stock Price, News & Analysis - MarketBeat

2 weeks from now

2 days ago · 12 people have added Exelixis to their MarketBeat watchlist in the last 30 days. This is an increase of 140% compared to the previous 30 days. ... Exelixis price target raised to $37 …

marketbeat.com

$2.16
OFF

Exelixis Sets 2025 Guidance In Line With Estimates

2 weeks from now

2 days ago · Exelixis (NASDAQ:EXEL) expects $2.165B (consensus estimate: $2.17B) in total revenues for fiscal year 2024, with around ~$1.805B in net product revenues. The oncology …

seekingalpha.com

$30.00
OFF

Exelixis (NASDAQ:EXEL) Stock Price Expected To Rise, HC

2 weeks from now

5 days ago · UBS Group began coverage on Exelixis in a research note on Thursday, September 19th. They set a "neutral" rating and a $30.00 price objective on the stock. Wells Fargo & …

marketbeat.com

$26.00
OFF

Burney Co. Acquires New Position In Exelixis, Inc. (NASDAQ:EXEL)

2 weeks from now

1 day ago · Stifel Nicolaus raised their price target on Exelixis from $26.00 to $30.00 and gave the company a "hold" rating in a research report on Wednesday, October 16th. Finally, UBS …

marketbeat.com

FAQs about Exelixis (NASDAQ:EXEL) Price Target Raised to $42.00 - MarketBeat Coupon?

Is Exelixis a good stock to invest in?

Exelixis has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, based on 10 buy ratings, 4 hold ratings, and no sell ratings. Exelixis has only been the subject of 4 research reports in the past 90 days. ...

What is the approval rating of Exelixis' CEO?

75 employees have rated Exelixis Chief Executive Officer Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among the company's employees. ...

Where can I buy shares of Exelixis?

Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. ...

How much will Exelixis make in 2024?

Exelixis (NASDAQ: EXEL) expects $2.165B (consensus estimate: $2.17B) in total revenues for fiscal year 2024, with around ~$1.805B in net product revenues. The oncology company also set financial guidance for 2025, projecting $2.15B - $2.25B (consensus estimate: $2.19B) in revenues for the year with $1.95B-$2.05B in net product revenues. ...

What is the average rating score for Exelixis?

Exelixis has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 10 buy ratings, 4 hold ratings, and no sell ratings. Exelixis has only been the subject of 4 research reports in the past 90 days. ...

Who is the CEO of Exelixis?

Michael M. Morrissey is the CEO of Exelixis. He has an approval rating of 79% among the company's employees, with 75 employees rating him on Glassdoor.com. ...